Suraj Kalia
Stock Analyst at Oppenheimer
(3.65)
# 697
Out of 5,182 analysts
92
Total ratings
44.3%
Success rate
9.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $115 | $92.72 | +24.03% | 3 | Apr 17, 2026 | |
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $24.76 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $108.91 | +60.68% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $192.33 | +55.98% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $27.37 | - | 8 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $59.52 | +68.01% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $52.03 | +236.34% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $12.00 | +50.00% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $79.71 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $23.98 | -8.26% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $118.88 | +0.94% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $36.56 | -12.47% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $111.90 | -16.89% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.53 | +120.99% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.22 | +303.73% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $85.62 | +57.67% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $221.22 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $24.80 | +20.97% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.52 | +38,712.34% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $72.26 | +34.24% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $22.37 | +25.17% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $5.45 | -17.43% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.66 | +2,327.92% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $451.29 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.18 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $18.49 | +440.83% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $62.60 | - | 5 | Sep 12, 2018 |
Abbott Laboratories
Apr 17, 2026
Maintains: Outperform
Price Target: $132 → $115
Current: $92.72
Upside: +24.03%
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $24.76
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $108.91
Upside: +60.68%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $192.33
Upside: +55.98%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $27.37
Upside: -
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $59.52
Upside: +68.01%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $52.03
Upside: +236.34%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $12.00
Upside: +50.00%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $79.71
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $23.98
Upside: -8.26%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $118.88
Upside: +0.94%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $36.56
Upside: -12.47%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $111.90
Upside: -16.89%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.53
Upside: +120.99%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.22
Upside: +303.73%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $85.62
Upside: +57.67%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $221.22
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $24.80
Upside: +20.97%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.52
Upside: +38,712.34%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $72.26
Upside: +34.24%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $22.37
Upside: +25.17%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $5.45
Upside: -17.43%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $0.66
Upside: +2,327.92%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $451.29
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.18
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $18.49
Upside: +440.83%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $62.60
Upside: -